← Dyne Therapeutics overview

Dyne Therapeutics vs Alnylam Pharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Dyne Therapeutics Inc (DYN)

Q3 2026
▲3

Dyne advances DMD drug toward FDA decision, funds pipeline

  • FDA accepts DMD drug application with priority review The FDA accepted Dyne's application for z-rostudirsen in Duchenne muscular dystrophy and granted Priority Review, with a decision expected by January 21, 2027. This is a major step toward a potential U.S. launch in early 2027, boosting investor confidence in the company's lead program.

    This is the most significant regulatory milestone that directly affects DYN's path to revenue and is new information.

  • New FSHD drug program cleared for human testing Dyne received FDA clearance to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD). This expands the company's pipeline into a third disease area, showing the platform's broader potential and adding another shot at future growth.

    This is a new pipeline expansion that increases the company's long-term value proposition.

  • Company raises $375 million in stock sale, diluting shareholders Dyne priced an upsized $375 million public offering at $20.50 per share, which will fund its pipeline but dilutes existing shareholders. The stock fell 10.6% after the announcement, reflecting the near-term cost of raising capital for long-term goals.

    This is a major capital event that affects the share count and near-term stock price, and is new information.

  • Expanded debt facility adds up to $400 million for launches Dyne expanded its debt facility with Hercules Capital to up to $400 million, providing non-dilutive funding to advance its lead candidates toward potential launches. This strengthens the balance sheet without selling more shares, supporting the company's commercial preparations.

    This is a new financing event that improves liquidity and reduces reliance on equity dilution.

July 2026
▲3

Dyne advances DMD drug toward FDA decision, funds pipeline

  • FDA accepts DMD drug application with priority review The FDA accepted Dyne's application for z-rostudirsen in Duchenne muscular dystrophy and granted Priority Review, with a decision expected by January 21, 2027. This is a major step toward a potential U.S. launch in early 2027, boosting investor confidence in the company's lead program.

    This is the most significant regulatory milestone that directly affects DYN's path to revenue and is new information.

  • New FSHD drug program cleared for human testing Dyne received FDA clearance to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD). This expands the company's pipeline into a third disease area, showing the platform's broader potential and adding another shot at future growth.

    This is a new pipeline expansion that increases the company's long-term value proposition.

  • Company raises $375 million in stock sale, diluting shareholders Dyne priced an upsized $375 million public offering at $20.50 per share, which will fund its pipeline but dilutes existing shareholders. The stock fell 10.6% after the announcement, reflecting the near-term cost of raising capital for long-term goals.

    This is a major capital event that affects the share count and near-term stock price, and is new information.

  • Expanded debt facility adds up to $400 million for launches Dyne expanded its debt facility with Hercules Capital to up to $400 million, providing non-dilutive funding to advance its lead candidates toward potential launches. This strengthens the balance sheet without selling more shares, supporting the company's commercial preparations.

    This is a new financing event that improves liquidity and reduces reliance on equity dilution.

Latest
▲3

Dyne advances DMD drug toward FDA decision, funds pipeline

  • FDA accepts DMD drug application with priority review The FDA accepted Dyne's application for z-rostudirsen in Duchenne muscular dystrophy and granted Priority Review, with a decision expected by January 21, 2027. This is a major step toward a potential U.S. launch in early 2027, boosting investor confidence in the company's lead program.

    This is the most significant regulatory milestone that directly affects DYN's path to revenue and is new information.

  • New FSHD drug program cleared for human testing Dyne received FDA clearance to begin a Phase 1 trial of DYNE-302 in facioscapulohumeral muscular dystrophy (FSHD). This expands the company's pipeline into a third disease area, showing the platform's broader potential and adding another shot at future growth.

    This is a new pipeline expansion that increases the company's long-term value proposition.

  • Company raises $375 million in stock sale, diluting shareholders Dyne priced an upsized $375 million public offering at $20.50 per share, which will fund its pipeline but dilutes existing shareholders. The stock fell 10.6% after the announcement, reflecting the near-term cost of raising capital for long-term goals.

    This is a major capital event that affects the share count and near-term stock price, and is new information.

  • Expanded debt facility adds up to $400 million for launches Dyne expanded its debt facility with Hercules Capital to up to $400 million, providing non-dilutive funding to advance its lead candidates toward potential launches. This strengthens the balance sheet without selling more shares, supporting the company's commercial preparations.

    This is a new financing event that improves liquidity and reduces reliance on equity dilution.

Alnylam Pharmaceuticals Inc (ALNY)

Q3 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

July 2026
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Latest
▲2▼2

Alnylam's TTR Guidance Cut Triggers 29% Plunge Despite Record Quarter

  • TTR Guidance Cut Sends Shares Down 29% Alnylam lowered its 2026 TTR revenue guidance to $4.2–4.5 billion from $4.4–4.7 billion, citing slower second-line demand for Amvuttra. The stock plunged 29% as investors feared the flagship franchise's growth is decelerating, overshadowing strong Q2 results.

    This is the single biggest new event of the period and the main reason ALNY is moving right now.

  • Amvuttra Tops $1 Billion in a Quarter for First Time Amvuttra exceeded $1 billion in quarterly sales, with total product revenue up 74% and non-GAAP operating income tripling to $318 million. This shows the drug is still growing strongly, but the guidance cut signals the pace will slow.

    It is the key new financial result that contrasts with the guidance cut and explains the mixed market reaction.

  • Rival ATTR-CM Drug Fails, Boosting Alnylam's Competitive Edge AstraZeneca and Ionis's Wainua failed a Phase 3 ATTR-CM trial, removing a potential competitor. Alnylam shares initially rose 18% as its Amvuttra faces less competition in the cardiomyopathy market, though the later guidance cut reversed those gains.

    This is a major new competitive development that initially drove the stock up and remains a positive force.

  • Securities Fraud Investigation Adds Legal Uncertainty Kirby McInerney launched an investigation into potential securities law violations following the guidance cut. While no lawsuit has been filed, the probe adds uncertainty and could pressure the stock as investors weigh legal risks.

    It is a new negative development that could affect investor sentiment and is directly tied to the guidance cut.

Q2 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

June 2026
▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

▲4

Alnylam's RNAi Engine Roars: AI Deals, Regulatory Wins, and a 121% Revenue Surge

  • Amvuttra's 187% sales jump powers 121% total revenue growth Amvuttra sales soared 187% to $889.9 million, driving total Q1 product revenue up 121% to $1.04 billion. This blockbuster growth is the core reason Alnylam's stock can rebound, as it proves the company's flagship drug is winning in the cardiomyopathy market.

    This is the fundamental growth engine behind the stock's potential recovery and analyst optimism.

  • AI partnerships with Inceptive and Komodo aim to speed drug discovery and commercialization Alnylam formed a $2 billion AI collaboration with Inceptive Nucleics to accelerate RNAi drug discovery and expanded its Komodo Health partnership to scale AI analytics. These deals could shorten development timelines and boost pipeline productivity, supporting long-term growth.

    These new AI initiatives signal future pipeline expansion and operational efficiency, key for a biotech's valuation.

  • Cemdisiran accepted for FDA and EMA review in myasthenia gravis Regulators accepted marketing applications for cemdisiran, with FDA priority review and a November decision date. This milestone brings a potential new rare-disease therapy closer to market, diversifying revenue beyond Amvuttra and adding a near-term catalyst.

    A regulatory acceptance is a concrete step toward a new product approval, directly impacting future revenue.

  • Analysts see 45% upside as Brown Advisory initiates a position Wall Street's average price target is $436, about 45% above the recent close, and Brown Advisory initiated a stake citing an attractive entry point. These votes of confidence suggest the market may be undervaluing Alnylam's growth prospects.

    Institutional buying and analyst targets reflect external validation of the company's value after a steep selloff.

© 2026 MarketIVWhy